Sales & Earnings In Brief: Merck evaluates consumer business, Perrigo expects more nasal steroid switches, Pfizer consumer sales flat, Sanofi consumer grows nearly 10%
This article was originally published in The Tan Sheet
Executive Summary
Merck evaluates consumer business; Perrigo expects more nasal steroid switches; Pfizer consumer segment flat; Sanofi consumer sales grow nearly 10%; Bayer consumer slips; more Sales & Earnings In Brief
You may also be interested in...
“Likely” Merck Consumer-Health Sale Could Bring $8 Billion – Analysts
Merck executives shift their position regarding the potential divestiture of non-pharma assets, including the firm’s consumer-health business. J.P. Morgan analysts expect a sale of the consumer unit, and say Merck’s brands, including Claritin and Coppertone, could grow globally with a new owner.
Nasacort OTC Dual Allergy/Decongestion Relief Could Be Marketing Edge
Sanofi’s Nasacort likely can carve out sales in the crowded nonprescription allergy market with promises of allergy relief plus decongestion in a product available OTC, unlike most competitors including Claritin D, Zyrtec D and Allegra D, which contain pseudoephedrine and are sold behind-the-counter.
Pfizer Reorganizes Internally, Closer To Decision On Splitting Business
Consumer health products are grouped with vaccines and oncology drugs in Pfizer’s internal reorganization that takes effect in January 2014. Pfizer’s realignment into three organizations represents a step in the firm’s multi-year deliberation over whether to split its business.